No Data
No Data
Wanbangde Pharmaceutical Holding Group (002082.SZ): Orphan drugs and rare disease drugs certified by the FDA have not yet entered the clinical trial stage.
On July 31st, Gleaming Healthcare (002082.SZ) stated on the investor interactive platform that the company is committed to bringing better clinical benefits to global patients. The orphan drugs and rare pediatric disease recognition by the US FDA have laid a good regulatory and registration foundation for the international development of products. At present, the FDA's new drug application (IND) is being processed normally and clinical trials have not yet begun.
Wanbangde Pharmaceutical Holding Group (002082.SZ) equity distribution in 2023: 0.8 yuan per 10 shares.
Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that their annual equity distribution plan for 2023 is as follows: based on the company's existing total share capital after deducting repurchased shares, every 10 shareholders will receive RMB 0.8 in cash (including taxes). The registration day for equity distribution is July 10, 2024, and the ex-rights and ex-dividend day is July 11, 2024.
Wan Bond (002082.SZ): Huperzine A's indication for neonatal hypoxic ischemic encephalopathy was certified as an orphan drug by the US FDA
Wanbond (002082.SZ) issued an announcement. Wanbond Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of the company, announced in 202...
Wan Bond (002082.SZ): Zhao Shouming, one of the actual controllers, completed a 1.188% increase in shares
Gelonghui, May 24 | Wan Bond (002082.SZ) announced that as of the announcement disclosure date, Mr. Zhao Shouming, one of the actual controllers, chairman and general manager of the company, had increased his holdings of the company's shares by 7,326,900 shares through centralized bidding transactions on the Shenzhen Stock Exchange, accounting for 1.1881% of the company's current total share capital. The amount of increase in holdings was 32.777.78 million yuan. The implementation of this share increase plan was completed.
Chairman Wan Bond (002082.SZ) increased his total share holdings by 1.19%
Wan Bond (002082.SZ) issued an announcement. As of May 8, 2024, the time for this holdings increase plan has passed...
US FDA Gives Rare Pediatric Disease Drug Designation to Wanbangde Pharmaceutical's Huperzine A
No Data